Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06898489
Active, not recruiting Observational

Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort Study

NCT06898489 · tracked via the Priya Life Science China tracker
Sponsor
Yijun Luo
Phase
Observational
Started
2025-03-01
Last updated
2025-03-27

Condition(s) studied

Systemic Lupus ErythematosusMusic Therapy

Investigational drug(s) / intervention(s)

Yu-Tone Music InterventionConventional pharmacotherapy

Yu-Tone Music Intervention: SLE patients undergo a structured Yu-tone music listening program (30 minutes daily, 5 days per week, with each cycle lasting 8 weeks, for a total of 3 cycles

Conventional pharmacotherapy: Standard SLE medications (e.g., hydroxychloroquine, glucocorticoids).

Study summary

The goal of this observational study is to investigate the long-term adjunctive effects of Traditional Chinese Five-Tone Therapy (Yu Tone) in patients with systemic lupus erythematosus (SLE). The main question it aims to answer is:

Does Yu-tone music therapy improve psychological well-being and quality of life in SLE patients when used as a complementary intervention alongside standard pharmacotherapy? Participants already receiving Yu-tone music therapy as part of their integrative care for SLE will complete validated online questionnaires assessing psychological distress (e.g., anxiety, depression), disease-related quality of life, and medication adherence monthly for 2 years.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Meet the 2019 ACR/EULAR classification criteria for SLE; ② Adults aged 18 years or older; ③ Provide informed consent to participate in the study. Exclusion Criteria: * Presence of severe organ dysfunction (e.g., renal failure, cardiac insufficiency) or psychiatric disorders; ② Diagnosed with hearing impairment or auditory disorders; ③ Inability to comprehend or complete study questionnaires (e.g., due to cognitive impairment or language barriers).

Primary outcome measure(s)

  • SLEDAI score — From enrollment to the treatment at 12 weeks

Trial sites (1)

FacilityCityRegionStatus
Hangzhou, 310053, China. Hangzhou China

Other trials for the same condition

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE Recruiting
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) Starting soon
A Study of E6742 in Participants With Systemic Lupus Erythematosus Recruiting
CHT105 for the Treatment of Refractory Lupus Nephritis Enrolling by invitation
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06898489 on ClinicalTrials.gov ↗ ← All trials in China